These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

469 related articles for article (PubMed ID: 26597098)

  • 1. Present and Future Therapies in Neuromyelitis Optica Spectrum Disorders.
    Kleiter I; Gold R
    Neurotherapeutics; 2016 Jan; 13(1):70-83. PubMed ID: 26597098
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of effect of empirical attack-preventive immunotherapies in neuromyelitis optica spectrum disorders: An update systematic review and meta -analysis.
    Ma J; Yu H; Wang H; Zhang X; Feng K
    J Neuroimmunol; 2022 Feb; 363():577790. PubMed ID: 34959021
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD) - revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part II: Attack therapy and long-term management.
    Kümpfel T; Giglhuber K; Aktas O; Ayzenberg I; Bellmann-Strobl J; Häußler V; Havla J; Hellwig K; Hümmert MW; Jarius S; Kleiter I; Klotz L; Krumbholz M; Paul F; Ringelstein M; Ruprecht K; Senel M; Stellmann JP; Bergh FT; Trebst C; Tumani H; Warnke C; Wildemann B; Berthele A;
    J Neurol; 2024 Jan; 271(1):141-176. PubMed ID: 37676297
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness of treatments in Neuromyelitis optica to modify the course of disease in adult patients. Systematic review of literature.
    Velasco M; Zarco LA; Agudelo-Arrieta M; Torres-Camacho I; Garcia-Cifuentes E; Muñoz O
    Mult Scler Relat Disord; 2021 May; 50():102869. PubMed ID: 33711580
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of neuromyelitis optica spectrum disorders.
    Romeo AR; Segal BM
    Curr Opin Rheumatol; 2019 May; 31(3):250-255. PubMed ID: 30920972
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neuromyelitis optica spectrum disorders: from pathophysiology to therapeutic strategies.
    Carnero Contentti E; Correale J
    J Neuroinflammation; 2021 Sep; 18(1):208. PubMed ID: 34530847
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neuromyelitis Optica (Devic's Syndrome): an Appraisal.
    Crout TM; Parks LP; Majithia V
    Curr Rheumatol Rep; 2016 Aug; 18(8):54. PubMed ID: 27402111
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hope for patients with neuromyelitis optica spectrum disorders - from mechanisms to trials.
    Pittock SJ; Zekeridou A; Weinshenker BG
    Nat Rev Neurol; 2021 Dec; 17(12):759-773. PubMed ID: 34711906
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adverse Events in NMOSD Therapy.
    Giglhuber K; Berthele A
    Int J Mol Sci; 2022 Apr; 23(8):. PubMed ID: 35456972
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advances in the Treatment of Neuromyelitis Optica Spectrum Disorder.
    Wallach AI; Tremblay M; Kister I
    Neurol Clin; 2021 Feb; 39(1):35-49. PubMed ID: 33223088
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of mycophenolate mofetil in the treatment of neuromyelitis optica spectrum disorders: An update systematic review and meta -analysis.
    Wang Y; Ma J; Chang H; Zhang X; Yin L
    Mult Scler Relat Disord; 2021 Oct; 55():103181. PubMed ID: 34365314
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of azathioprine, mycophenolate mofetil, and rituximab in the treatment of neuromyelitis optica spectrum disorder and analysis of prognostic factors.
    Zhang L; Tian J; Dong X; Jia Z; Sun Y; Guo L; Tan G; Li B
    Neurol Sci; 2022 Apr; 43(4):2651-2658. PubMed ID: 34585292
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monoclonal antibody therapy for neuromyelitis optica spectrum disorder: current and future.
    Lin J; Xue B; Li X; Xia J
    Int J Neurosci; 2017 Aug; 127(8):735-744. PubMed ID: 27680606
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Experience with tocilizumab in patients with neuromyelitis optica spectrum disorders.
    Carreón Guarnizo E; Hernández Clares R; Castillo Triviño T; Meca Lallana V; Arocas Casañ V; Iniesta Martínez F; Olascoaga Urtaza J; Meca Lallana JE
    Neurologia (Engl Ed); 2022 Apr; 37(3):178-183. PubMed ID: 35465911
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-IL-6 Therapies for Neuromyelitis Optica Spectrum Disorders: A Systematic Review of Safety and Efficacy.
    Lotan I; McGowan R; Levy M
    Curr Neuropharmacol; 2021; 19(2):220-232. PubMed ID: 32348222
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Blockade of IL-6 signaling in neuromyelitis optica.
    Araki M
    Neurochem Int; 2019 Nov; 130():104315. PubMed ID: 30342072
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Moving towards a new era for the treatment of neuromyelitis optica spectrum disorders.
    Preziosa P; Amato MP; Battistini L; Capobianco M; Centonze D; Cocco E; Conte A; Gasperini C; Gastaldi M; Tortorella C; Filippi M
    J Neurol; 2024 Jul; 271(7):3879-3896. PubMed ID: 38771385
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Seropositive Neuromyelitis Optica in a Case of Undiagnosed Ankylosing Spondylitis: A Neuro-Rheumatological Conundrum.
    Ghosh Md R; Roy D; León-Ruiz M; Das S; Dubey S; Benito-León J
    Qatar Med J; 2022; 2022(3):29. PubMed ID: 35864917
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent advances in the treatment of neuromyelitis optica spectrum disorders.
    Romeo AR
    Curr Opin Rheumatol; 2021 May; 33(3):233-239. PubMed ID: 33741809
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Disease course, progression and activity of neuromyelitis optica (NMOSD) in patients who were treated with Rituximab, 6 and 12 months after receiving the first dose of drug, in Isfahan city.
    Ashtari F; Mehdipour R; Shaygannejad V; Mansourian M
    Mult Scler Relat Disord; 2019 Sep; 34():77-82. PubMed ID: 31233958
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.